Neurocrine banks $20M as endometriosis drug advances to PhIII

Abbott Labs and Neurocrine Biosciences ($NBIX) recently sat down with FDA regulators to outline plans for a late-stage study of their experimental endometriosis drug elagolix, triggering a $20 million milestone payment to the biotech. "This represents another significant step forward for the elagolix program as it readies for pivotal studies and we remain confident that Abbott has the right resources devoted to elagolix to enable it to be both a clinical and commercial success," said Neurocrine CEO Kevin Gorman. Release

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.